Questioning the role of palmitoylethanolamide in psychosis: a systematic review of clinical and preclinical evidence
Open Access
- 18 July 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 14, 1231710
Abstract
Introduction: The endocannabinoid (eCB) system disruption has been suggested to underpin the development of psychosis, fueling the search for novel, better-tolerated antipsychotic agents that target the eCB system. Among these, palmitoylethanolamide (PEA), an N-acylethanolamine (AE) with neuroprotective, anti-inflammatory, and analgesic properties, has drawn attention for its antipsychotic potential.Methods: This Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020-compliant systematic review aimed at reappraising all clinical and preclinical studies investigating the biobehavioral role of PEA in psychosis.Results: Overall, 13 studies were eligible for data extraction (11 human, 2 animal). Observational studies investigating PEA tone in psychosis patients converged on the evidence for increased PEA plasma (6 human) and central nervous system (CNS; 1 human) levels, as a potential early compensatory response to illness and its severity, that seems to be lost in the longer-term (CNS; 1 human), opening to the possibility of exogenously supplementing it to sustain control of the disorder. Consistently, PEA oral supplementation reduced negative psychotic and manic symptoms among psychosis patients, with no serious adverse events (3 human). No PEA changes emerged in either preclinical psychosis model (2 animal) studied.Discussion: Evidence supports PEA signaling as a potential psychosis biomarker, also indicating a therapeutic role of its supplementation in the disorder.Systematic review registration: https://doi.org/10.17605/OSF.IO/AFMTK.Keywords
This publication has 62 references indexed in Scilit:
- Mast cell–glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamidePhilosophical Transactions of the Royal Society B: Biological Sciences, 2012
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophreniaTranslational Psychiatry, 2012
- Genetics and intermediate phenotypes of the schizophrenia—bipolar disorder boundaryNeuroscience & Biobehavioral Reviews, 2010
- The Kraepelinian dichotomy – going, going … but still not goneThe British Journal of Psychiatry, 2010
- Shared genetics of bipolar disorder and schizophreniaNature Reviews Neurology, 2009
- Psychosis Genetics: Modeling the Relationship Between Schizophrenia, Bipolar Disorder, and Mixed (or "Schizoaffective") PsychosesSchizophrenia Bulletin, 2009
- Cost-effectiveness of antipsychotics for outpatients with chronic schizophreniaInternational Journal Of Clinical Practice, 2007
- Cerebrospinal Anandamide Levels are Elevated in Acute Schizophrenia and are Inversely Correlated with Psychotic SymptomsNeuropsychopharmacology, 2004
- Die Erscheinungsformen des IrreseinsHistory of Psychiatry: Madness, Science, Culture, 1992
- Introductory remarks on the translation of Emil Kraepelin's paper Die Erscheinungsformen des Irreseins (1920)History of Psychiatry: Madness, Science, Culture, 1992